The Optimal Treatment for Treatment-resistant Schizophrenia

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The Optimal Treatment for Treatment-resistant Schizophrenia

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Treatments: Aripiprazole; Clozapine; Risperidone; Valproic Acid

Criteria

Inclusion Criteria:

• The diagnosis of schizophrenia according to DSM-V

• 18～60 years old

• 2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;

• Signed an informed consent

Exclusion Criteria:

• patients to be diagnosed according to DSM-V for substance abused, development delayed

• suffering from serious physical disease and can not accept the treatment

• MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure

• allergic to risperidone ,aripiprazole, or sodium valproate

• Participated in any clinical subject within 30 days

• Pregnancy or lactation